-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
-
FDA Approves Claritin For OTC Use For Seasonal Rhinitis; Simpler Atrial Fibrillation Management; Oral Anticoagulation Vs Aspirin in AF; Immunization Does Not Cause Autism; Statins May Lower CRP Levels; Simvastatin Reduced CRP Plasma Levels; FDA Actions
-
Effects of Losartan on Cardiovascular Morbidity and Mortality in
Patients with Isolated Systolic Hypertension and LVH; Increase in
Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1
Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and
Nondiabetic Postmenopausal Women; Effects of Long-Term Treatment With
ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks
Associated with Atrial Fibrillation: 20-Year Follow-up of the
Renfrew/Paisley Study; Olfactory Impairment in Older Adults
-
Currently, there are no medications specifically approved in the United States for treatment of the advanced stages of Alzheimers disease (AD). Results of the first US large-scale, prospective, double-blind study of memantine in the treatment of moderate-to-severe AD indicate that memantine-treated advanced AD patients fare better than those who received placebo, with no significant treatment-related side effects.
-
Confavreux and colleagues studied 1844 multiple sclerosis (MS) patients enrolled in a large European database up until 1997. Clinical variables were identified early in the course of the disease, and their continued prognostic significance was determined after the first stages of irreversible neurological disability.
-
There is little doubt that cerebrovascular disease is a major contributor to cognitive decline in the elderly. Recurrent symptomatic strokes affecting cortical or subcortical function inevitably result in a stepwise burden of accumulating damage and disability.
-
Consider this all-too-familiar scenario. Patient X awakens from otherwise uneventful abdominal surgery and complains of ulnar nerve distribution weakness or tingling, or both. Ulnar neuropathy at the elbow (UNE) is documented, litigation ensues, and large sums of money exchange hands. Who is guilty and of what?
-
Inhibition of thromboxane A2 synthesis by aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) underlies the risk of bleeding complications associated with their use. Aspirin use is associated with a reduced risk of thrombotic events and possibly an increased risk for intracerebral hemorrhage (ICH).
-
A number of neurotrophic factors have great promise for the treatment of neurologic diseases. Prior work showed that a number of neurotrophic factors appeared to have promise for treating ALS, as well as peripheral neuropathy.
-
This is the first reported clinical trial of the effects of creatine in sporadic ALS patients. The trial was carried out in The Netherlands.
